Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Intestinal Pseudo-Obstruction Treatment Market Growth Potential: How Will Market Size Shift Through 2030?
The intestinal pseudo-obstruction treatment market size has demonstrated robust growth in recent years. This market is anticipated to expand from $24.74 billion in 2025 to $26.01 billion in 2026, registering a compound annual growth rate (CAGR) of 5.1%. The historical growth can be attributed to several factors including a limited understanding of gastrointestinal motility disorders, increased hospitalization for unexplained bowel obstruction symptoms, reliance on symptomatic drug therapies, advancements in diagnostic imaging and motility testing, and the growth in specialist gastroenterology clinics.
The intestinal pseudo-obstruction treatment market size is projected to experience substantial growth in the coming years, with an estimated increase to $33.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.1%. This expansion during the forecast period can be attributed to intensifying research into intestinal motility disorders, an increasing demand for personalized IPO treatment strategies, the rising adoption of advanced diagnostic techniques, the expansion of multidisciplinary gastroenterology care, and improved clinical guidelines for rare GI disorders. Prominent trends anticipated within this forecast period include a heightened focus on the early and accurate diagnosis of IPO, the growing utilization of multimodal symptom management approaches, an increasing embrace of conservative and non-surgical treatments, the broadening of long-term disease management and supportive care, and enhanced awareness of rare gastrointestinal motility disorders.
Get A Free Sample Report With In-Depth Market Insights:
Intestinal Pseudo-Obstruction Treatment Market Growth Momentum: What Factors Are Shaping Demand?
An anticipated surge in Parkinson’s disease cases is projected to significantly boost the intestinal pseudo-obstruction treatment market. This neurodegenerative condition specifically targets dopamine-producing neurons within the brain’s substantia nigra region. Individuals with Parkinson’s disease experience a higher occurrence of IPO, largely due to the disease’s impact on the enteric nervous system, which leads to gastrointestinal dysmotility and subsequent issues like megacolon or intestinal blockage, such as acute colonic pseudo-obstruction. For example, Sutter Health, a US-based nonprofit healthcare network, reported that in July 2025, an estimated 1.1 million people in the United States were living with Parkinson’s disease in 2025, with projections indicating a rise to 1.2 million by 2030. Consequently, the escalating number of Parkinson’s disease cases is a key driver for the expansion of the intestinal pseudo-obstruction treatment market.
Intestinal Pseudo-Obstruction Treatment Market Segments: Where Is Growth Concentrated?
The intestinal pseudo-obstruction treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics, Antidepressants, Antidiarrheals
2) By Treatment: Medication, Surgery, Diet, Decompression, Other Treatments
3) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
4) By Diagnosis: Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Other Diagnosis
5) By End User: Clinic, Hospitals, Other End Users
Subsegments:
1) By Antibiotics: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics
2) By Antidepressants: Tricyclic Antidepressants (TCAs), Selective Serotonin Reuptake Inhibitors (SSRIs)
3) By Antidiarrheals: Loperamide, Bismuth Subsalicylate
Intestinal Pseudo-Obstruction Treatment Market Key Participants And Competitive Landscape
Major companies operating in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Allergan plc, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd, Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.
View The Full Intestinal Pseudo-Obstruction Treatment Market Report:
Intestinal Pseudo-Obstruction Treatment Market Regional Analysis And Top Geography
North America was the largest region in the intestinal pseudo-obstruction treatment market in 2025. The regions covered in the intestinal pseudo-obstruction treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
